Pulmonary complications of tyrosine kinase inhibitors and immune checkpoint inhibitors in patients with non-small cell lung cancer

Gupta, Kushagra; Uchel, Toribiong; Karamian, Gregory; Loschner, Anthony L.

doi:10.1016/j.ctarc.2021.100439

Cited by 1 publication

(2 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Risk factors for the development of ILD are preexisting ILD, male sex, older age, history of tobacco smoking, worse performance status [67]. The symptoms characteristic for rapid onset of ILD comprise of worsening dry cough and dyspnea within days to weeks [68,69]. The diagnosis is made on the basis of chest X-ray or high-resolution computerized tomography of the chest after exclusion of pneumonia and cancer progression [70].…”

Section: Pulmonary Toxicitymentioning

confidence: 99%

See 1 more Smart Citation

Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review

Marjański

Dziedzic

Kowalczyk

et al. 2021

IJMS

View full text Add to dashboard Cite

New drugs, including immune checkpoint inhibitors and targeted therapy, have changed the prognosis in a subset of patients with advanced lung cancer, and are now actively investigated in a number of trials with neoadjuvant and adjuvant regimens. However, no phase III randomized studies were published yet. The current narrative review proves that targeted therapies are safe in neoadjuvant approach. Unsurprisingly, administration of therapy is related to an acceptable toxicity profile. Severe adverse events’ rate that rarely compromises outcomes of patients with advanced lung cancer is not that commonly accepted in early lung cancer as it may lead to missing the chance of curative surgery. Among those complications, the most important factors that may limit the use of targeted therapies are severe respiratory adverse events precluding the resection occurring after treatment with some anaplastic lymphoma kinase and rarely after epidermal growth factor receptor tyrosine kinase inhibitors. At this point, in the presented literature assessing the feasibility of neoadjuvant therapies with anaplastic lymphoma kinase and epidermal growth factor receptor tyrosine kinase inhibitors, we did not find any unexpected intraoperative events that would be of special interest to a thoracic surgeon. Moreover, the postoperative course was associated with typical rate of complications.

show abstract

Section: Pulmonary Toxicitymentioning

confidence: 99%

“…Negative cultures obtained in bronchoalveolar lavage obviously do not preclude infectious origin of pulmonary infiltrates, which may require molecular testing for various pathogens responsible for interstitial pneumonia. Treatment discontinuation and steroids are the only interventions offered when ILD after EGFR-TKIs occurs [26,69].…”

Section: Pulmonary Toxicitymentioning

confidence: 99%